NO320074B1 - Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. - Google Patents
Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. Download PDFInfo
- Publication number
- NO320074B1 NO320074B1 NO19981189A NO981189A NO320074B1 NO 320074 B1 NO320074 B1 NO 320074B1 NO 19981189 A NO19981189 A NO 19981189A NO 981189 A NO981189 A NO 981189A NO 320074 B1 NO320074 B1 NO 320074B1
- Authority
- NO
- Norway
- Prior art keywords
- proteosome
- determinant
- amphiphile
- vaccine according
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 58
- 229940031348 multivalent vaccine Drugs 0.000 title claims abstract description 11
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 112
- 239000002158 endotoxin Substances 0.000 claims abstract description 111
- 238000004519 manufacturing process Methods 0.000 claims abstract description 40
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 23
- 241000607760 Shigella sonnei Species 0.000 claims abstract description 20
- 238000011026 diafiltration Methods 0.000 claims abstract description 17
- 241000606999 Plesiomonas shigelloides Species 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 11
- 238000012544 monitoring process Methods 0.000 claims abstract description 7
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 239000003599 detergent Substances 0.000 claims abstract description 3
- 241000607762 Shigella flexneri Species 0.000 claims abstract 2
- 239000004094 surface-active agent Substances 0.000 claims description 32
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical group CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 19
- 239000012466 permeate Substances 0.000 claims description 19
- 239000012510 hollow fiber Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 14
- 239000012465 retentate Substances 0.000 claims description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 241000607768 Shigella Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 241000588653 Neisseria Species 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 229940115939 shigella sonnei Drugs 0.000 claims description 8
- 230000004888 barrier function Effects 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 241000607766 Shigella boydii Species 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 241000607000 Plesiomonas Species 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 30
- 238000000502 dialysis Methods 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 16
- 238000011109 contamination Methods 0.000 abstract description 8
- 230000007423 decrease Effects 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 238000010668 complexation reaction Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 241000147000 Shigella flexneri 2a Species 0.000 description 15
- 230000005847 immunogenicity Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 206010040550 Shigella infections Diseases 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 208000004429 Bacillary Dysentery Diseases 0.000 description 10
- 201000005113 shigellosis Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 101710116435 Outer membrane protein Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 238000011194 good manufacturing practice Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 238000013341 scale-up Methods 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 238000011146 sterile filtration Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010028921 Lipopeptides Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002434 immunopotentiative effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012500 good manufacturing practice method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- -1 liposaccharides Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US385995P | 1995-09-18 | 1995-09-18 | |
| PCT/US1996/015002 WO1997010844A1 (en) | 1995-09-18 | 1996-09-18 | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981189D0 NO981189D0 (no) | 1998-03-17 |
| NO981189L NO981189L (no) | 1998-05-14 |
| NO320074B1 true NO320074B1 (no) | 2005-10-17 |
Family
ID=21707938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981189A NO320074B1 (no) | 1995-09-18 | 1998-03-17 | Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6476201B1 (ru) |
| EP (1) | EP0854729B2 (ru) |
| JP (2) | JP4033489B2 (ru) |
| KR (1) | KR19990045763A (ru) |
| CN (1) | CN1211192A (ru) |
| AT (1) | ATE261313T1 (ru) |
| BR (1) | BR9610484A (ru) |
| CA (1) | CA2232410C (ru) |
| CZ (1) | CZ298460B6 (ru) |
| DE (1) | DE69631835T3 (ru) |
| DK (1) | DK0854729T3 (ru) |
| EA (1) | EA199800208A1 (ru) |
| ES (1) | ES2217325T5 (ru) |
| HU (1) | HUP9901577A3 (ru) |
| IL (1) | IL123720A (ru) |
| MX (1) | MX9802128A (ru) |
| NO (1) | NO320074B1 (ru) |
| PL (1) | PL325604A1 (ru) |
| PT (1) | PT854729E (ru) |
| WO (1) | WO1997010844A1 (ru) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| PT1079857E (pt) * | 1998-05-29 | 2007-02-28 | Statens Inst For Folkehelse | Combinação de vacinas para a meningite b e c |
| NZ581940A (en) | 1999-04-30 | 2011-07-29 | Novartis Vaccines & Diagnostic | Conserved neisserial antigens |
| NZ528254A (en) * | 1999-05-19 | 2005-07-29 | Chiron S | Combined neisserial compositions |
| EP1721618A3 (en) * | 2000-02-15 | 2007-01-10 | ID Biomedical Corporation of Quebec | Proteosome influenza vaccine composition |
| ATE331530T1 (de) | 2000-02-15 | 2006-07-15 | Id Biomedical Corp Quebec | Proteasom-influenzavirus-impfstoffzusammensetzu g |
| WO2001064922A2 (en) | 2000-02-28 | 2001-09-07 | Chiron Spa | Heterologous expression of neisserial proteins |
| AU2002245636B2 (en) | 2001-03-09 | 2004-10-14 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
| EP2481419A3 (en) * | 2002-08-02 | 2013-04-10 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccines |
| CA2501812C (en) | 2002-10-11 | 2012-07-10 | Mariagrazia Pizza | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| GB0316560D0 (en) * | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| JP2007505836A (ja) * | 2003-09-15 | 2007-03-15 | アイディー バイオメディカル コーポレイション オブ ケベック | 麻疹サブユニットワクチン |
| CA2543080C (en) | 2003-10-22 | 2019-01-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| ES2432369T3 (es) | 2004-06-25 | 2013-12-03 | Id Biomedical Corporation Of Quebec | Composiciones y métodos para tratar trastornos neurológicos |
| US20060286124A1 (en) * | 2004-06-30 | 2006-12-21 | Id Biomedical Corporation Of Quebec | Vaccine compositions and methods of treating coronavirus infection |
| US7552948B2 (en) | 2006-03-29 | 2009-06-30 | Tokai Rubber Industries, Ltd. | Quick connector |
| WO2008021076A2 (en) * | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Protein matrix vaccines and methods of making and administering such vaccines |
| CN101553246B (zh) * | 2006-08-07 | 2019-05-21 | 哈佛大学校长及研究员协会 | 蛋白质基质疫苗及这种疫苗的制备和给药方法 |
| US20100288029A1 (en) * | 2006-08-30 | 2010-11-18 | Ge Healthcar Bio-Sciences Corp. | System and method for characterizing membranes and membrane filtration devices |
| WO2009158142A1 (en) * | 2008-05-30 | 2009-12-30 | The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| EP2473188A4 (en) * | 2009-09-09 | 2014-01-01 | Matrivax Res & Dev Corp | PROTEIN MATRIX VACCINES WITH IMPROVED IMMUNOGENICITY |
| AU2015321698B2 (en) * | 2014-09-24 | 2018-06-28 | The United States Of America As Represented By The Secretary Of The Navy | Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| RU1522494C (ru) * | 1987-06-16 | 1994-11-15 | Научно-производственное объединение "Иммунопрепарат" | Способ получения инактивированной вакцины гриппа |
| RU2023448C1 (ru) * | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| US5145702A (en) * | 1988-09-19 | 1992-09-08 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles and preparation thereof |
| ES2070312T5 (es) * | 1988-12-19 | 2003-05-16 | American Cyanamid Co | Vacuna de proteina de membrana exterior meningococica de clase 1. |
| US5102989A (en) * | 1991-03-15 | 1992-04-07 | Merck & Co., Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells |
| AU4683093A (en) * | 1992-07-20 | 1994-02-14 | Merck & Co., Inc. | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| WO1995011700A1 (en) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| ATE331530T1 (de) * | 2000-02-15 | 2006-07-15 | Id Biomedical Corp Quebec | Proteasom-influenzavirus-impfstoffzusammensetzu g |
-
1996
- 1996-09-18 AT AT96932269T patent/ATE261313T1/de not_active IP Right Cessation
- 1996-09-18 CN CN96197616A patent/CN1211192A/zh active Pending
- 1996-09-18 PT PT96932269T patent/PT854729E/pt unknown
- 1996-09-18 WO PCT/US1996/015002 patent/WO1997010844A1/en active IP Right Grant
- 1996-09-18 BR BR9610484-8A patent/BR9610484A/pt not_active Application Discontinuation
- 1996-09-18 DE DE69631835T patent/DE69631835T3/de not_active Expired - Lifetime
- 1996-09-18 CA CA002232410A patent/CA2232410C/en not_active Expired - Lifetime
- 1996-09-18 US US09/043,529 patent/US6476201B1/en not_active Expired - Lifetime
- 1996-09-18 HU HU9901577A patent/HUP9901577A3/hu unknown
- 1996-09-18 PL PL96325604A patent/PL325604A1/xx unknown
- 1996-09-18 CZ CZ0081998A patent/CZ298460B6/cs not_active IP Right Cessation
- 1996-09-18 ES ES96932269T patent/ES2217325T5/es not_active Expired - Lifetime
- 1996-09-18 KR KR1019980702007A patent/KR19990045763A/ko not_active Application Discontinuation
- 1996-09-18 EP EP96932269A patent/EP0854729B2/en not_active Expired - Lifetime
- 1996-09-18 JP JP51287597A patent/JP4033489B2/ja not_active Expired - Lifetime
- 1996-09-18 EA EA199800208A patent/EA199800208A1/ru unknown
- 1996-09-18 DK DK96932269T patent/DK0854729T3/da active
- 1996-09-18 IL IL12372096A patent/IL123720A/en not_active IP Right Cessation
-
1998
- 1998-03-17 NO NO19981189A patent/NO320074B1/no not_active IP Right Cessation
- 1998-03-18 MX MX9802128A patent/MX9802128A/es unknown
-
2003
- 2003-10-24 JP JP2003365270A patent/JP2004099619A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR9610484A (pt) | 2001-09-11 |
| IL123720A (en) | 2002-02-10 |
| NO981189L (no) | 1998-05-14 |
| HUP9901577A3 (en) | 2000-03-28 |
| DE69631835T2 (de) | 2005-02-10 |
| ES2217325T3 (es) | 2004-11-01 |
| JP2004099619A (ja) | 2004-04-02 |
| KR19990045763A (ko) | 1999-06-25 |
| CZ81998A3 (cs) | 1998-10-14 |
| IL123720A0 (en) | 1998-10-30 |
| EP0854729A1 (en) | 1998-07-29 |
| EP0854729A4 (en) | 2000-02-02 |
| CN1211192A (zh) | 1999-03-17 |
| CA2232410C (en) | 2003-06-17 |
| US6476201B1 (en) | 2002-11-05 |
| DK0854729T3 (da) | 2004-07-12 |
| CZ298460B6 (cs) | 2007-10-10 |
| MX9802128A (es) | 1998-11-29 |
| EP0854729B1 (en) | 2004-03-10 |
| DE69631835T3 (de) | 2009-03-05 |
| ES2217325T5 (es) | 2009-04-01 |
| HUP9901577A2 (hu) | 1999-08-30 |
| PT854729E (pt) | 2004-08-31 |
| WO1997010844A1 (en) | 1997-03-27 |
| EA199800208A1 (ru) | 1998-10-29 |
| DE69631835D1 (de) | 2004-04-15 |
| PL325604A1 (en) | 1998-08-03 |
| US20020164357A1 (en) | 2002-11-07 |
| ATE261313T1 (de) | 2004-03-15 |
| JP2000507913A (ja) | 2000-06-27 |
| JP4033489B2 (ja) | 2008-01-16 |
| EP0854729B2 (en) | 2008-10-22 |
| NO981189D0 (no) | 1998-03-17 |
| CA2232410A1 (en) | 1997-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320074B1 (no) | Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. | |
| CA2123355C (en) | Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci | |
| US6558677B2 (en) | Vaccine against gram negative bacteria | |
| Collins | Gram-negative outer membrane vesicles in vaccine development | |
| US11339367B2 (en) | Hyperblebbing Shigella strains | |
| Levine et al. | Fimbrial vaccines | |
| Frasch et al. | Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens | |
| Frasch et al. | Outer membrane protein vesicle vaccines for meningococcal disease | |
| US20040131642A1 (en) | Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof | |
| BE1022875B1 (fr) | Compositions pour une immunisation contre staphylococcus aureus | |
| WO2012049662A1 (en) | Hyperblebbing salmonella strains | |
| Muttilainen et al. | TheNeisseria meningitidisouter membrane protein P1 produced inBacillus subtilisand reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes | |
| AU751063B2 (en) | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines | |
| Ito et al. | Homologous prime-boost strategy in neonate mice using Neisseria lactamica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |